|
Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus
RECRUITINGSponsored by Cardenal Herrera University
Actively Recruiting
SponsorCardenal Herrera University
Started2026-01-25
Est. completion2026-01-28
Eligibility
Age40 Years – 69 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07373938
Summary
This study aims to compare carotid intima-media thickness (CIMT) and layer-specific texture characteristics of the carotid wall between individuals with Type 2 diabetes mellitus (T2DM) and normoglycemic controls, to assess the impact of T2DM on these ultrasound variables and evaluate their ability to discriminate between low and high cardiovascular risk at 10 years.
Eligibility
Age: 40 Years – 69 YearsHealthy volunteers accepted
Inclusion Criteria * European adults. * Age between 40 and 69 years. * Confirmed diagnosis of type 2 diabetes mellitus. * No established cardiovascular disease. * Availability of the required clinical and metabolic variables: Age; Sex; Systolic blood pressure; Non-high-density lipoprotein (non-HDL) cholesterol; Smoking status; Duration of diabetes; Glycated hemoglobin (HbA1c); Presence or absence of diabetes-related target organ damage (e.g., albuminuria, retinopathy) Exclusion Criteria * History of clinical cardiovascular disease (secondary prevention). * Type 1 diabetes mellitus. * Patients with established severe target organ damage or conditions that automatically classify them as very high cardiovascular risk according to ESC guidelines. * Advanced chronic kidney disease (estimated glomerular filtration rate \<30 mL/min/1.73 m²).
Conditions2
DiabetesType 2 Diabetes Mellitus
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorCardenal Herrera University
Started2026-01-25
Est. completion2026-01-28
Eligibility
Age40 Years – 69 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07373938